Aim-The Captia Syph G enzyme immuno assay (EAI) offers the potential for the rapid automated detection of syphilis antibodies. This study was designed to assess the role of other sexually transmitted diseases (STDs) in producing false positive reactions in the Captia Syph G EIA. The role of rheumatoid factor (RF) as a potential source of false positives was also analysed.
Introduction
The recent introduction of the Captia Enzyme Immunoassay (Captia Syph G) to detect immunoglobulin G (IgG) antibodies against Treponema pallidum presents an opportunity for automated processing and reporting for large numbers of specimens.'3 This EIa test with an overall sensitivity of over 98% and specificity of over 99%2 is comparable in performance with the traditional combination of VDRL (Venereal Disease Research Laboratory) and TPHA (Treponema pallidum Haemagglutination Assay) tests even in primary syphilis.' False negatives in the EIA were associated specifically with primary infection where the sensitivity was 82%. False positive reactions were not associated with conventional Biological False Positive Reactors. 3 The incidence of syphilis in general, and the primary stage in particular, is low in the United Kingdom, however, and the occurrence of false positive reactions, albeit at a low level, decreases the positive predictive value of a positive test. The factors responsible for these erroneous Our results indicate that false positive EIA reactions are commoner in an STD population when compared with antenatal women but are not associated with any individual STD. The lower incidence of genital warts in patients with false positive tests compared with the control clinic population is difficult to explain. Warts are controlled mainly via cell mediated immunity and humoral factors are thought to be relatively unimportant. 7 There were fewer women in the false positive reactor group than the clinic population as a whole but this was not statistically significant. In this context it is interesting that the incidence of false positive IgG EIA results was lower in the group of pregnant women studied compared with the GUM population (p < 0-01). Since pregnant women are generally in more stable relationships than the GUM clinic population and are therefore less likely to have genital infections this may indicate that STDs do contribute to false positive reactions. Many other physiological changes in immunity and hormones also occur in pregnancy however and it is unclear as to the relative contribution of these different factors.
Women have a higher incidence of autoimmune diseases in general8 but this may not be an important factor in determining a serological false positive reaction in this assay in view of the sex ratio observed in the false positive patients.
Rheumatoid factor, usually in the form of immunoglobulin M (IgM) directed against host IgG, is well recognised in syphilis and increases in incidence in the latter stages of the disease.9 The IgM-IgG complex may produce a false positive reaction by mimicking IgM specific antibody in EIA reactions. The absence of any false positive reactions would indicate that rheumatoid factor is not important in producing false positive reactions in the Captia Syph G EIA system, however. RF would also not appear to be a problem in the IgM EIA as evidenced by the very low number of false positive IgM reactions.
It is also possible that false positive reactions may occur owing to the presence of heat shock proteins'0 and endofiagella present in the sonicate of Treponema pallidum" 12
In conclusion, no individual sexually transmitted disease is associated with false positive reactions in the Captia Syph G EIA although false reactivity is commoner in an STD population than in pregnant women. This may suggest that the cause of these reactions is multifactorial or due to a different mechanism. Despite a low positive predictive value the test is comparable to traditional screening methods with regard to sensitivity and specificity but is potentially cheaper when large numbers of samples are processed, particularly by automated systems.
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